Compositions and methods of use for opioid hexadienoates and optionally substituted hexadienoates
The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' engagement of the opioid receptors when given orally. A 3-hexadienoate modification of nalbuphine or a pharmaceutically acceptable salt of thereof to improve quality of pain management when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation. A 3-hexadienoate modification of the opioids antagonists is formulated to improve inhibition of the opioid receptors when given orally. A 3-hexadienoate modification of naloxone or a pharmaceutically acceptable salt of thereof to improve quality of Sobering when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation.
1. A method for treating a disease or condition, comprising administering an effective amount of a composition to a patient in need of such treatment, wherein said composition comprises a modified opioid, wherein said modified opioid is 3-allyl-4a-hydroxy-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl-(2E,4E)-hexa-2,4-dienoate, and wherein said disease or condition is an opioid addiction, pruritis or a dyskinesia associated with Tourette's syndrome.
2. A method for treating a disease or condition, comprising administering an effective amount of a composition to a patient in need of such treatment, wherein said composition comprises a modified opioid, wherein said modified opioid is 3-(cyclobutylmethyl)-4a, 7-dihydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl (2E,4E)-hexa-2,4-dienoate, and wherein said disease or condition is pruritis or pain.
3. The method of claim 1 , wherein said disease or condition is an opioid addiction.
4. The method of claim 1 , wherein said disease or condition is pruritis.
5. The method of claim 1 , wherein said disease or condition is a dyskinesia associated with Tourette's syndrome.
6. The method of claim 2 , wherein said disease or condition is pruritis.
7. The method of claim 2 , wherein said disease or condition is pain.
8. A method for treating or preventing opioid overdose, comprising administering an effective amount of a composition to a patient who has taken an opioid, wherein said composition comprises a modified opioid, wherein said modified opioid is 3-allyl-4a-hydroxy-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl -(2E,4E)-hexa-2,4-dienoate.